DE69422724T2 - 1,2,4 - TRIAZOLO[1,5-a]PYRIMIDINE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON NEUROLOGISCHEN ERKRANKUNGEN - Google Patents

1,2,4 - TRIAZOLO[1,5-a]PYRIMIDINE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON NEUROLOGISCHEN ERKRANKUNGEN

Info

Publication number
DE69422724T2
DE69422724T2 DE69422724T DE69422724T DE69422724T2 DE 69422724 T2 DE69422724 T2 DE 69422724T2 DE 69422724 T DE69422724 T DE 69422724T DE 69422724 T DE69422724 T DE 69422724T DE 69422724 T2 DE69422724 T2 DE 69422724T2
Authority
DE
Germany
Prior art keywords
alkyl
halo
cyano
hydroxy
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69422724T
Other languages
English (en)
Other versions
DE69422724D1 (de
Inventor
David J Heal
Fernandez Maria Isab Fernandez
Bruce G Sargent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Application granted granted Critical
Publication of DE69422724D1 publication Critical patent/DE69422724D1/de
Publication of DE69422724T2 publication Critical patent/DE69422724T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE69422724T 1993-10-13 1994-10-12 1,2,4 - TRIAZOLO[1,5-a]PYRIMIDINE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON NEUROLOGISCHEN ERKRANKUNGEN Expired - Lifetime DE69422724T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939321162A GB9321162D0 (en) 1993-10-13 1993-10-13 Therapeutic agents
PCT/EP1994/003364 WO1995010521A1 (en) 1993-10-13 1994-10-12 Therapeutic agents

Publications (2)

Publication Number Publication Date
DE69422724D1 DE69422724D1 (de) 2000-02-24
DE69422724T2 true DE69422724T2 (de) 2000-09-07

Family

ID=10743505

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69422724T Expired - Lifetime DE69422724T2 (de) 1993-10-13 1994-10-12 1,2,4 - TRIAZOLO[1,5-a]PYRIMIDINE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON NEUROLOGISCHEN ERKRANKUNGEN

Country Status (31)

Country Link
US (1) US5753665A (de)
EP (1) EP0723546B1 (de)
JP (1) JPH09503771A (de)
CN (1) CN1040537C (de)
AT (1) ATE188966T1 (de)
AU (1) AU679573B2 (de)
BG (1) BG62405B1 (de)
BR (1) BR9407812A (de)
CA (1) CA2173857A1 (de)
CZ (1) CZ106996A3 (de)
DE (1) DE69422724T2 (de)
DK (1) DK0723546T3 (de)
ES (1) ES2142413T3 (de)
FI (1) FI961630A (de)
GB (1) GB9321162D0 (de)
GR (1) GR3032480T3 (de)
HU (1) HUT74580A (de)
IL (1) IL111259A (de)
IN (1) IN179169B (de)
MY (1) MY112110A (de)
NO (1) NO306509B1 (de)
NZ (1) NZ274500A (de)
PL (1) PL177920B1 (de)
PT (1) PT723546E (de)
RO (1) RO117020B1 (de)
RU (1) RU2136684C1 (de)
SK (1) SK282329B6 (de)
TW (1) TW372237B (de)
UA (1) UA42738C2 (de)
WO (1) WO1995010521A1 (de)
ZA (1) ZA947949B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506382D0 (en) * 1995-03-29 1995-05-17 Boots Co Plc Pharmaceutical compositions
GB9507348D0 (en) * 1995-04-08 1995-05-31 Knoll Ag Therapeutic agents
US5714607A (en) * 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
BR9710729A (pt) 1996-07-25 1999-08-17 Merck Sharp & Dohme Composto composi-Æo farmac-utica utiliza-Æo de um composto e processo para o tratamento e/ou a preven-Æo da ansiedade e de convuls{es para a triagem de compostos ansioliticos nÆo-sedativos e para a prepara-Æo de um composto
GB9617727D0 (en) * 1996-08-23 1996-10-02 Knoll Ag Process
GB9626746D0 (en) * 1996-12-23 1997-02-12 Knoll Ag Process
DE19706337A1 (de) * 1997-02-19 1998-08-20 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Estern
DE19706336A1 (de) * 1997-02-19 1998-08-20 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Alkoholen
DE19707008A1 (de) 1997-02-21 1998-08-27 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Alkoholen
ES2291043T3 (es) * 1998-10-16 2008-02-16 MERCK SHARP & DOHME LIMITED Derivados de pirazolotriazina como ligandos para receptores de gaba.
GB9906124D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Therapeutic agent
GB9906130D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Compounds for use in therapy
GB9906126D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Pharmaceutical formulations
GB9914743D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
GEP20053688B (en) * 2000-06-30 2005-12-12 Wyeth Corp Substituted-Triazolopyrimidines as Anticancer Agents
KR100783255B1 (ko) 2004-02-13 2007-12-06 워너-램버트 캄파니 엘엘씨 안드로젠 수용체 조절제
WO2005100305A1 (en) 2004-04-13 2005-10-27 Warner-Lambert Company Llc Androgen modulators
WO2005102990A1 (en) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Androgen modulators
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
MX2011002278A (es) 2008-08-29 2011-04-14 Concert Pharmaceuticals Inc Derivados de triazolo-piridazina sustituidos.
DK2414365T3 (da) 2009-04-01 2014-03-31 Aniona Aps SUBSTITUEREDE [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINER OG ANVENDELSE HERAF SOM KALIUMKANALMODULATORER
WO2010112485A1 (en) 2009-04-01 2010-10-07 Neurosearch A/S SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
WO2010112484A1 (en) * 2009-04-01 2010-10-07 Neurosearch A/S SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
CA3138307A1 (en) 2019-05-13 2020-11-19 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE46306B1 (en) * 1977-02-11 1983-05-04 Ici Ltd Safeguarded toxic chemical compositions containing an emetic
WO1989001478A1 (en) * 1987-08-07 1989-02-23 The Australian National University ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES
US5387747A (en) * 1992-02-24 1995-02-07 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present

Also Published As

Publication number Publication date
ES2142413T3 (es) 2000-04-16
FI961630A0 (fi) 1996-04-12
PL313970A1 (en) 1996-08-05
SK43796A3 (en) 1996-10-02
HUT74580A (en) 1997-01-28
IN179169B (de) 1997-09-06
RO117020B1 (ro) 2001-09-28
UA42738C2 (uk) 2001-11-15
NO961435D0 (no) 1996-04-11
EP0723546A1 (de) 1996-07-31
AU679573B2 (en) 1997-07-03
PT723546E (pt) 2000-04-28
CA2173857A1 (en) 1995-04-20
WO1995010521A1 (en) 1995-04-20
NO306509B1 (no) 1999-11-15
FI961630A (fi) 1996-04-12
IL111259A (en) 1998-02-08
AU7855494A (en) 1995-05-04
JPH09503771A (ja) 1997-04-15
HU9600959D0 (en) 1996-06-28
CN1040537C (zh) 1998-11-04
NO961435L (no) 1996-06-10
IL111259A0 (en) 1995-03-30
BG100485A (bg) 1996-11-29
CZ106996A3 (en) 1996-09-11
ZA947949B (en) 1996-01-23
ATE188966T1 (de) 2000-02-15
BR9407812A (pt) 1997-05-06
DK0723546T3 (da) 2000-05-01
NZ274500A (en) 1997-06-24
RU2136684C1 (ru) 1999-09-10
GB9321162D0 (en) 1993-12-01
BG62405B1 (bg) 1999-10-29
US5753665A (en) 1998-05-19
CN1135754A (zh) 1996-11-13
EP0723546B1 (de) 2000-01-19
PL177920B1 (pl) 2000-01-31
TW372237B (en) 1999-10-21
DE69422724D1 (de) 2000-02-24
MY112110A (en) 2001-04-30
GR3032480T3 (en) 2000-05-31
SK282329B6 (sk) 2002-01-07

Similar Documents

Publication Publication Date Title
DE69422724D1 (de) 1,2,4 - TRIAZOLO[1,5-a]PYRIMIDINE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON NEUROLOGISCHEN ERKRANKUNGEN
EP0636025A4 (en) Compounds useful for treating allergic or inflammatory diseases.
CA2119511A1 (en) Benzimidazole compounds, their use and preparation
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
ATE385238T1 (de) Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände
GEP20033029B (en) Substituted 1,8-Naphthyridin-4(1H)-Ones as Phosphodiesterase 4 Inhibitors
NO951797L (no) Terapeutiske midler
PL313941A1 (en) Alkoxyalkyl carbamates of imidazo /1,2-a/ pyrimidines
GB9418912D0 (en) Pharmaceutically active compounds
AR032653A1 (es) Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
NZ333869A (en) Alpha-amino acid amides and their use in the treatment of neurodegenerative diseases
BG102080A (en) Amino acid derivatives of substituted quinoxalin 2,3-dion derivatives such as glutamate receptor antagonists
MY110773A (en) 1-arylcycloalky1 sulphides, sulphoxides and sulphones, processes for their preparation, and their use in the treatment of depression, anxiety and parkinson''s disease.
SG82540A1 (en) N-substituted azabicyclo [3.2.0] heptane derivatives as neuroleptics, the preparation and use thereof
IE894039L (en) Therapeutic agents
EP0489925A4 (en) Pyrimidine compound and pharmaceutically acceptable salt thereof
JO1833B1 (en) Therapeutic agents
MXPA01009384A (es) Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina.
ES2123836T3 (es) Imidazo(1,5-a)quinoleinas para el tratamiento de la ansiedad y trastornos del sueño.
ES2087813A1 (es) Heterociclos no-aromaticos que contienen nitrogeno bencilamino substituidos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ABBOTT GMBH & CO. KG, 65205 WIESBADEN, DE